Back to search

Article

ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degeneration

2019-12-19

Abstract excerpt

Under the ATN framework, cerebrospinal fluid analytes provide evidence of the presence or absence of Alzheimer’s disease pathological hallmarks: amyloid plaques (A), phosphorylated tau (T), and accompanying neurodegeneration (N). Still, differences in cerebrospinal fluid levels across amnestic and non-amnestic variants or due to co-occurring pathologies might lead to misdiagnoses. We assess the diagnostic accuracy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6fae5e67-139c-54a3-9cc1-941e6703189c
DOI
10.1101/2019.12.18.881441
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ATN status in amnestic and non-amnestic Alzheimer’s disease and frontotemporal lobar degenerationDOI 10.1101/2019.12.18.881441
Structural heterogeneity reveals distinct amyloidopathies in Alzheimer’s diseaseSemantic proximity
Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluidSemantic proximity
CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal DementiasSemantic proximity
Clinicopathological and prognostic correlations of plasma biomarkers in neurodegenerative diseasesSemantic proximity
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group.Semantic proximity
CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysisSemantic proximity
Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.Semantic proximity
The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.Semantic proximity
Performance of Plasma Amyloid β, Total Tau and Neurofilament Light Chain Levels for Alzheimer’s Disease IdentificationSemantic proximity
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine ApproachSemantic proximity
Optimal Combinations of Biomarkers to Determine AT(N) in the Alzheimer’s Disease Semantic proximity
Phosphorylated Tau-Aβ42 Ratio as a Continuous Trait for Biomarker Discovery for Early-Stage Alzheimer’s Disease in Multiplex Immunoassay Panels of Cerebrospinal FluidSemantic proximity
Select a neighboring publication to make it the new centre.